Literature DB >> 8476778

Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women.

T Noguchi1, J Kitawaki, T Tamura, T Kim, H Kanno, T Yamamoto, H Okada.   

Abstract

Aromatase activity, as well as steroid receptors, exists in nonfunctional ovarian tumors. Steroid receptor status has been reported to be related to prognosis in ovarian cancer patients. We determined aromatase activity and progesterone receptor (PR) and estrogen receptor (ER) levels in 43 ovarian tumors obtained from postmenopausal women. Aromatase activity was detected in 35 tumors (81%), PR in 21 tumors (49%) and ER in 13 tumors (30%). Eighty-three percent (10/12) of mucinous cystadenoma tissues showed positive PR with high aromatase activity, while 93% (13/14) of malignant tumors showed negative PR and low aromatase activity. Aromatase activity was detected in 95% (20/21) of PR-positive tumors, being greater than in PR-negative tumors (P < 0.002). There was a positive correlation between aromatase activity and PR (rs = 0.49, P < 0.001). However, there was no correlation between aromatase activity and ER. In 17 patients (43%), the serum estradiol level was higher than 30 pg/ml and there was a positive correlation among estradiol, estrone, androstenedione and testosterone. However, serum steroid levels were not correlated with aromatase activity, PR or ER. Aminoglutethimide inhibited aromatase activity of benign and malignant ovarian tumors, uterine myoma, choriocarcinoma cells and purified human placental P-450arom in a similar manner. These results suggest that aromatase activity is correlated with PR in ovarian tumors of postmenopausal women. In addition to steroid receptor status, aromatase activity may be a useful prognostic factor in ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8476778     DOI: 10.1016/0960-0760(93)90275-2

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  9 in total

1.  Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events.

Authors:  Nathan J Charles; Peter Thomas; Carol A Lange
Journal:  Horm Cancer       Date:  2010-08       Impact factor: 3.869

2.  Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.

Authors:  K M Lau; S C Mok; S M Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

3.  Aromatase in human common epithelial ovarian neoplasms.

Authors:  K Kaga; H Sasano; N Harada; M Ozaki; S Sato; A Yajima
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

4.  Local estrogen metabolism in epithelial ovarian cancer suggests novel targets for therapy.

Authors:  Xia Ren; Xuan Wu; Stephen G Hillier; K Scott Fegan; Hilary O D Critchley; J Ian Mason; Sana Sarvi; Christopher R Harlow
Journal:  J Steroid Biochem Mol Biol       Date:  2015-03-24       Impact factor: 4.292

Review 5.  Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis.

Authors:  Hui Luo; Saisai Li; Menghuang Zhao; Bo Sheng; Haiyan Zhu; Xueqiong Zhu
Journal:  Oncotarget       Date:  2017-05-30

6.  The role of hormonal factors and endocrine therapy in ovarian cancer.

Authors:  Krystyna Serkies; Marcin Sinacki; Jacek Jassem
Journal:  Contemp Oncol (Pozn)       Date:  2013-03-15

7.  A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.

Authors:  N J McKenna; D G Kieback; D N Carney; M Fanning; J McLinden; D R Headon
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

Review 8.  Estrogen, progesterone and epithelial ovarian cancer.

Authors:  Shuk-Mei Ho
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

9.  Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors.

Authors:  Jun-Ichi Akahira; Takashi Suzuki; Kiyoshi Ito; Chika Kaneko; Andrew D Darnel; Takuya Moriya; Kunihiro Okamura; Nobuo Yaegashi; Hironobu Sasano
Journal:  Jpn J Cancer Res       Date:  2002-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.